Mount Sinai Neurobiologist Selected as Howard Hughes Medical Institute Investigator miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Less than eight months after unveiling its Biomedical Laureates Program, the Icahn School of Medicine at Mount Sinai announced today the first Laureates.
Marquis Who s Who Takes a Fresh Look at STEM to Recognize American Influencers and Innovators for the May Installment of the Maker s List
Marquis also recognizes Asian American and Pacific Island Americans of influence in celebration of AAPI Heritage Month
News provided by
Share this article
Share this article
UNIONDALE, N.Y., May 3, 2021 /PRNewswire/ Marquis Who s Who (MWW), the world s leading biographical publisher, has released the May edition of the Maker s List to recognize
Influencers and
Innovators in STEM. For this month s list, MWW has reimagined the traditional definition of STEM to highlight Science, Technology, Education and Medicine. The Maker s List features some of the most influential individuals in their respective fields, selected from thousands of professionals across the country. Spearheaded by
E-Mail
IMAGE: Eric J. Nestler, Dean for Academic and Scientific Affairs and Director of the Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai and senior author of the. view more
Credit: Mount Sinai Health System
An epigenetic modification that occurs in a major cell type in the brain s reward circuitry controls how stress early in life increases susceptibility to additional stress in adulthood, researchers at the Icahn School of Medicine at Mount Sinai have learned. In a study in
Nature Neuroscience, the team also reported that a small-molecule inhibitor of the enzyme responsible for this modification, currently being developed as an anti-cancer drug, was able to reverse increased vulnerability to lifelong stress in animal models.
EpiVario Establishes Scientific Advisory Board
Share Article
EpiVario
Bringing deep expertise in the areas of neuroscience, psychology, and epigenetics, these individuals will help EpiVario with its ongoing research efforts to utilize novel medical and scientific discoveries for the development of therapeutics for memory- and addiction-related diseases. - Dr. Berger PHILADELPHIA (PRWEB) February 16, 2021
EpiVario, Inc., a preclinical stage drug discovery and development company, today announced the formation of a Scientific Advisory Board (SAB) comprised of leading experts in neuroscience, psychology, and epigenetics. The SAB will guide and advise the Company on the translation of core discoveries into the research and development of therapeutic approaches for memory-related psychiatric disorders, including PTSD, drug and alcohol use disorder, and Alzheimer’s disease.